PTIX (Protagenic Therapeutics) Cyclically Adjusted FCF per Share: $-9.19 (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PTIX Protagenic Therapeutics Inc PTIX
22 GF Score
Price $0.18
! 2 Warning Signs
View Full Analysis

What is Protagenic Therapeutics Cyclically Adjusted FCF per Share?

Protagenic Therapeutics PTIX +8.02% 22 Cyclically Adjusted FCF per Share is $-9.19 as of Dec. 2025. GuruFocus rates PTIX with a GF Score™ of 22/100. The stock has 2 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Protagenic Therapeutics's adjusted free cash flow per share for the three months ended in Dec. 2025 was $-0.264. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $-9.19 for the trailing ten years ended in Dec. 2025.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was -6.30% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was -8.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Protagenic Therapeutics was 13.80% per year. The lowest was -9.30% per year. And the median was -3.45% per year.

As of today (2026-08-01), Protagenic Therapeutics's current stock price is $0.18. Protagenic Therapeutics's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2025 was $-9.19. Protagenic Therapeutics's Cyclically Adjusted Price-to-FCF of today is .


Protagenic Therapeutics  (OTCPK:PTIX) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Protagenic Therapeutics Cyclically Adjusted FCF per Share Related Terms


Protagenic Therapeutics Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Protagenic Therapeutics's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Protagenic Therapeutics Cyclically Adjusted FCF per Share Chart

Protagenic Therapeutics Annual Data
Trend Jun15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -6.84 -8.00 -8.22 -8.94 -9.60

Protagenic Therapeutics Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -9.60 -9.68 -9.53 -9.43 -9.19

PTIX vs CERO, CYTOF, CARM: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, Protagenic Therapeutics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Protagenic Therapeutics Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Protagenic Therapeutics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Protagenic Therapeutics's Cyclically Adjusted Price-to-FCF falls into.


PTIX
22GF Score
Protagenic Therapeutics Inc PTIX
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Protagenic Therapeutics Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Protagenic Therapeutics's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2025 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Dec. 2025 (Change)*Current CPI (Dec. 2025)
=-0.264/324.0540*324.0540
=-0.264

Current CPI (Dec. 2025) = 324.0540.

Protagenic Therapeutics Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201603 0.000 238.132 0.000
201606 -3.771 241.018 -5.070
201609 -2.085 241.428 -2.799
201612 -1.869 241.432 -2.509
201703 -1.951 243.801 -2.593
201706 -1.350 244.955 -1.786
201709 -1.962 246.819 -2.576
201712 -2.279 246.524 -2.996
201803 -1.415 249.554 -1.837
201806 -1.885 251.989 -2.424
201809 -0.874 252.439 -1.122
201812 -1.683 251.233 -2.171
201903 -1.071 254.202 -1.365
201906 -0.443 256.143 -0.560
201909 -0.339 256.759 -0.428
201912 -0.814 256.974 -1.026
202003 -1.989 258.115 -2.497
202006 -0.798 257.797 -1.003
202009 -2.831 260.280 -3.525
202012 -1.707 260.474 -2.124
202103 -3.234 264.877 -3.957
202106 -2.741 271.696 -3.269
202109 -3.644 274.310 -4.305
202112 -1.324 278.802 -1.539
202203 -1.399 287.504 -1.577
202206 -2.741 296.311 -2.998
202209 -1.731 296.808 -1.890
202212 -0.586 296.797 -0.640
202303 -1.208 301.836 -1.297
202306 -4.958 305.109 -5.266
202309 -2.123 307.789 -2.235
202312 -3.643 306.746 -3.849
202403 -5.233 312.332 -5.429
202406 -4.896 314.175 -5.050
202409 -0.574 315.301 -0.590
202412 -1.855 315.605 -1.905
202503 -2.042 319.799 -2.069
202506 -0.315 322.561 -0.316
202509 -0.754 324.800 -0.752
202512 -0.264 324.054 -0.264

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of $-9.19 mean?
Protagenic Therapeutics (PTIX) has a Cyclically Adjusted FCF per Share of $-9.19 as of Dec. 2025. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Protagenic Therapeutics and its competitors.
Is Protagenic Therapeutics' Cyclically Adjusted FCF per Share too high?
Protagenic Therapeutics' current Cyclically Adjusted FCF per Share is $-9.19. Overall, Protagenic Therapeutics has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Protagenic Therapeutics' Cyclically Adjusted FCF per Share compare to CERO and CYTOF?
Protagenic Therapeutics' Cyclically Adjusted FCF per Share of $-9.19 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Protagenic Therapeutics and its competitors. Protagenic Therapeutics's current Cyclically Adjusted FCF per Share is $-9.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Protagenic Therapeutics stock overvalued right now?
Protagenic Therapeutics (PTIX) has a current Cyclically Adjusted FCF per Share of $-9.19. The current Cyclically Adjusted FCF per Share is $-9.19. Protagenic Therapeutics' overall GF Score™ is 22/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Protagenic Therapeutics (PTIX), the current Cyclically Adjusted FCF per Share is $-9.19 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Protagenic Therapeutics Business Description

Address 149 Fifth Avenue, Suite 500, New York, NY, USA, 10010
Protagenic Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It provides treatments for mood, anxiety, depression, and neurodegenerative disorders by using peptide-based and brain-active therapeutics. The company's main compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. It has also created a portfolio of novel neuropeptides that are in various stages of development and preclinical evaluation for the treatment of mood disorders.
22GF Score

Get the complete analysis for PTIX

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.18
Price